Andrei V. Strygin

Andrei V. Strygin

Auto-generated profile, based on publicly available information

Andrei V. Strygin

Volgograd State Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
EAE. E. Abrosimova
E. E. Abrosimova
DBD. A. Bakulin
D. A. Bakulin
NKN. S. Kovalev
N. S. Kovalev
MDM. A. Dubrovina
M. A. Dubrovina
ITI. N. Tyurenkov
I. N. Tyurenkov
Nitric oxide as a therapeutic approach to the treatment of cardiovascular diseases attracted the attention of researchers at the end of the 19th century. As a vasodilator, nitric oxide may be a unique therapeutic agent for the treatment of hypertension and, as a result, renal failure and left ventricular hypertrophy.The aim of the article is to analyze the literature data on possible ways of modulating the activity of various nitric oxide synthases as an approach to the treatment of endothelial dysfunction.Materials and methods. When searching for materials for writing a review article, such abstract databases as PubMed, Google Scholar, e-Library, etc., were used. The search was carried out on the publications for the period from 1990 to 2021. The following words and phrases were chosen as parameters for the literature selection: nitric oxide; NO synthase; endothelial dysfunction; NO synthase activator; NO synthase inhibitor.The following words and phrases were chosen as parameters for the literature selection:Results. The article presents the history of the nitric oxide discovery and its biological role, the process of its biosynthesis, as well as the isoforms of its synthesizing enzymes (NOS): neuronal – nNOS, endothelial – eNOS and inducible iNOS, and their role in normal and pathological physiology. The process of NOS uncoupling (its molecular mechanisms) has been considered as the basis of endothelial dysfunction.The examples of the pharmacological correction (BH4, arginase inhibitors, statins, resveratrol) are presented. In addition, NO synthase activators (calcium dobesilate, cavNOxin, and some NOS transcription activators), as well as non-selective (L-NMMA, 1-NNA, L-NAME, ADMA, 546C88, VAS203) and selective (L-NIO, 7-nitroindazole, aminoguanidine, L-NIL, GW273629, GW274150, cavtratin) inhibitors of nitric oxide synthasehave been described.Conclusion. Nitric oxide synthases continue to be promising targets for the development of agents that modulate their activity to correct various pathologies. As a therapeutic approach, modulation of the nitric oxide synthase activity can be implemented to treat endothelial dysfunction, which is the cause for complications of many diseases.

9 January 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
DBD. A. Bakulin
D. A. Bakulin
EMEvgeny Morkovin
Evgeny Morkovin
VPV. I. Petrov
V. I. Petrov
ASA. V. Strygin
A. V. Strygin
ACA. N. Chumachenko
A. N. Chumachenko
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.

24 January 2024 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
DBD. A. Bakulin
D. A. Bakulin
ARA. I. Robertus
A. I. Robertus
YKYu. A. Kolosov
Yu. A. Kolosov
IKI. S. Krysanov
I. S. Krysanov
OIO. V. Ivanova
O. V. Ivanova
2021 marks the 100th anniversary of the discovery of insulin, an event that forever changed the lives of people with diabetes mellitus. At present patients around the world experience the miracle of insulin therapy every day. A disease that used to kill children and teenagers in 2 years in 1920 has become a disease that can be controlled with a possibility to lead a long productive life. Over the past century, the great discovery of Banting, Best and Collip has forever changed the world and saved millions of lives. This review is devoted to the history of the development of insulin and its further improvement: from the moment of discovery to the present days. Various generations of insulin are considered: from animals to modern ultrashort and basal analogues. The article ends with a brief review of current trends in the development of new delivery methods and the development of new insulin molecules. Over the past century, insulin therapy has come a long way, which has significantly improved the quality of life of our patients. But research is actively continuing, including in the field of alternative methods of insulin delivery, which are more convenient for the patient, as well as in the development of «smart» molecules that will have a glucose-dependent effect.

29 December 2022 in Journal of Volgograd State Medical University
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
EMEvgeny Morkovin
Evgeny Morkovin
DBD.A. Bakulin
D.A. Bakulin
YGYu.V. Gorbunova
Yu.V. Gorbunova
ASA.V. Strygin
A.V. Strygin
ДВДрай Р. В
Драй Р. В
In Russia, type 2 diabetes affects more than 5 % of the population. Type 2 diabetes accounts for up to 95 % of all cases of diabetes mellitus, but its pathogenetic mechanisms have not yet been fully established.Aim. To summarize and analyze the literature data on the pathogenetic links of type 2 diabetes mellitus. Materials and methods. When searching for material for writing a review article, abstract databases PubMed, Google Scholar, e-Library, etc. were used. The search was carried out by publications for the period 1960–2022. The following words and phrases were chosen as parameters for literature selection: pathogenesis of type 2 diabetes mellitus; insulin resistance;endothelial dysfunction; β-cells in type 2 diabetes; inflammation and diabetes, glucose utilization.Results. The article presents the concept of normal glucose metabolism, the role of the loss of functional mass of β-cells, aspects of the synthesis and metabolismof glucose by the liver, the role of muscle tissue in the consumption of glucose, as well as the role of the kidneys in the development of a vicious circle of diabetic hyperglycemia. The role of vascular andmyocardial resistance to insulin, adipose inflammation, the "ominous octet" is considered. The place of insulin resistance in the development of obesity was determined, the issues of incretin effects and liver diseases associated with diabetes were raised.Conclusion. The generalized informationwill expand and deepen knowledge about the pathogenesis of type 2 diabetes mellitus, which, in turn, will serve as a potential basis for new approaches in the treatment of one of the most common diseases of the 21st century.

28 April 2023 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
DBD. A. Bakulin
D. A. Bakulin
EMEvgeny Morkovin
Evgeny Morkovin
ASA. V. Strygin
A. V. Strygin
YGYu. V. Gorbunova
Yu. V. Gorbunova
VPV. I. Petrov
V. I. Petrov
Modern requirements for the treatment of type 2 diabetes mellitus (DM2) include not only achieving a glycemic control, but also reducing the risk of developing cardiovascular complications. Dipeptidyl peptidase 4 (DPP-4) inhibitors are inferior in the effectiveness to some other actively developing groups of hypoglycemic drugs (SGLT2 inhibitors and GLP-1 receptor agonists); however, they seem relevant at the present time.The aim of the study is to analyze the literature data on the therapeutic potential and results of the of DPP-4 inhibitors research.Materials and methods. When searching for the review article materials, the abstracting databases of PubMed, Google Scholar and e-Library were used. The search was carried out on the publications for the period from 2006 to 2022, using the following keywords: DPP-4 inhibitors; glucagonlike peptide-1 (GLP-1); glucose-dependent insulinotropic peptide (GIP); sitagliptin, and other drugs.Results. DPP-4 belongs to the serine proteases family and is involved in the degradation of various chemokines and peptide hormones, including incretins secreted by intestinal L- and K-cells – GLP-1 and GIP. They regulate a postprandial insulin secretion and a β-cell function, modulate a fasting and postprandial glucagon secretion, regulate the eating behavior and have many pleiotropic (immunomodulatory, anti-inflammatory, antifibrotic, etc.) effects. DPP-4 inhibitors reduce an enzyme activity by 70–90%, increasing plasma incretin levels by 2–4 times and have been used to treat DM2 since 2006. Now there are 13 DPP-4 inhibitors on the market in different countries, differing primarily in pharmacokinetic parameters. They are actively used in the combination therapy for type 2 diabetes, increasing the glycemic control effectiveness without increasing the risk of hypoglycemia. The evidence is emerging about the therapeutic potential of DPP-4 inhibitors in COVID-19.Conclusion. A peroral form, an ability to create effective combinations with other hypoglycemic drugs without increasing the risk of hypoglycemia, the pleiotropic effects of DPP-4 inhibitors, make this group relevant at the present time.

29 January 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
EMEvgeny Morkovin
Evgeny Morkovin
DBD. A. Bakulin
D. A. Bakulin
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
IMI. E. Makarenko
I. E. Makarenko
OIO. V. Ivanova
O. V. Ivanova
The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. The material for the analysis was taken from the abstract databases of PubMed, Google Scholar and e-library.ru. The search was carried out using publications for the period from 2008 to 2023, the keywords were as follows: “biologicals”, “new drug approval”, “drug authorization”, “drug development”, “biosimilar”, taking into account various spellings.Results. Over the past 15 years, scientists have been observing revolutionary trends and processes in the field of the drug development, especially biopharmaceuticals. Significant advances have been made in gene, immune and cell therapies, resulting in the approval of such drugs more than doubling over the past ten years. The development of biological drugs includes the identification and testing of molecular targets and requires a deep understanding of the structure and functioning of the polypeptides involved in the development of the effect. The features of these active pharmaceutical substances are a high molecular weight, a complex three-dimensional structure and a high immunogenic potential. Preclinical and clinical studies of biologics have unique challenges. Selecting appropriate animal species, understanding the immunogenicity, and assessing pharmacodynamics and toxicological properties require a multilevel, detailed approach. The article discusses the regulatory framework under which these drugs are registered, summarizing the guidelines provided by international organizations such as the International Council for Harmonization and various national agencies.Conclusion. The analysis highlights the current advances and prospects in the development of biologics, highlighting their key role in future transformations in the treatment of rare diseases and oncology, approaching the era of personalized medicine. Monitoring the development directions and technological approaches, as well as the commitment to global methodological and regulatory aspects can become a catalyst in the development of the Russian pharmacology.